A Study of PTC923 in Participants With Phenylketonuria
Status:
Recruiting
Trial end date:
2023-02-09
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to evaluate the efficacy of PTC923 in reducing blood
phenylalanine (Phe) levels in participants with phenylketonuria as measured by mean change in
blood Phe levels from baseline to Weeks 5 and 6 (that is, the average of each respective
treatment dose 2-week period of double-blind treatment).